FDA approves drug for infantile-onset Niemann-Pick type C after analysis finds longer survival

Medical Xpress - latest medical and health news stories ·
Health & Medicine United Kingdom

Researchers at the National Institutes of Health (NIH) and their collaborators at Beren Therapeutics, Thousand Oaks, California, have developed a treatment for infants with Niemann-Pick type C (NPC) disease, which is a rare and rapidly fatal pediatric neurodegenerative disorder. The drug, known as cyclodextrin (brand name Adrabetadex), extended the survival of participants with NPC in a large,…

Read original article on Medical Xpress - latest medical and health news stories →